OPKO HEALTH, INC. (eXegenics Inc.) - 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended March 31, 2007. The registrant, eXegenics Inc., is a development-stage company that recently underwent a three-way merger on March 27, 2007, with Froptix Corporation and Acuity Pharmaceuticals, Inc. Following the merger, the company began operating as OPKO Health, Inc. The entity is focused on developing innovative therapies for ophthalmic diseases, with its lead candidate being bevasiranib for the treatment of wet age-related macular degeneration (Wet AMD). For accounting purposes, the merger was treated as a reverse merger with Froptix as the accounting acquirer, and the acquisition of Acuity as an asset purchase.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2007 | Cumulative from Inception (Jun 23, 2006) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(250.8) million | $(250.8) million |
| Operating Expenses | $(250.8) million | $(250.8) million |
| Cash and Cash Equivalents | $17.1 million | $17.1 million |
| Total Assets | $17.5 million | $17.5 million |
| Total Liabilities | $10.7 million | $10.7 million |
| Shareholders' Equity | $6.7 million | $6.7 million |
| Accumulated Deficit | $(250.8) million | $(250.8) million |
Debt and Liquidity: The company holds a $12.0 million line of credit with The Frost Group (related party), with $4.0 million outstanding at period end. Additionally, the company assumed a $4.0 million term loan from Horizon Financial, Inc. Cash used in operating activities for the quarter was approximately $1.0 million, while financing activities provided approximately $16.9 million.
Material Changes and Unusual Items
- Merger and Acquisition: The most significant event was the March 27, 2007 merger. The company acquired Acuity Pharmaceuticals' assets in a stock-for-stock transaction. This resulted in a non-cash charge of $243.8 million for the write-off of acquired in-process research and development (IPR&D), which was immediately expensed.
- Capital Structure: The company issued significant equity to former shareholders of Froptix and Acuity, including 76.6 million shares of common stock and 457,589 shares of Series C preferred stock. As of March 31, 2007, there were 113.2 million shares of common stock outstanding.
- Stock-Based Compensation: Stock-based compensation expense for the quarter was approximately $6.0 million, primarily related to the assumed options from the acquired entities.
Outlook, Risks, and Management Commentary
Outlook: Management anticipates incurring substantial losses in future periods as the company continues the development of bevasiranib and prepares for Phase III clinical trials, expected to begin in the third or fourth quarter of 2007. The estimated cost for the Phase III trial is between $18 million and $20 million. The company expects to require additional funding before the end of 2008.
Liquidity: Management believes that cash on hand ($17.1 million) and the available credit line are sufficient to meet operational and debt service requirements for at least the next 12 months. Future financing needs will likely be met through private placements, public offerings, or strategic collaborations.
Risks:
- Development Risk: The company is highly dependent on the success of bevasiranib. There is no assurance of regulatory approval or successful commercialization.
- Financial Risk: As a development-stage company with no revenue, the company faces significant liquidity risks and must raise additional capital to continue operations.
- Regulatory Risk: Delays or rejections by the FDA or other regulatory authorities could materially impact the business.
Investor Verification Checklist
- Merger Accounting: Verify the treatment of the $243.8 million IPR&D write-off and its impact on the accumulated deficit.
- Cash Runway: Confirm the sufficiency of the $17.1 million cash balance against the projected $18-$20 million Phase III trial costs and ongoing operating expenses.
- Debt Covenants: Review the terms of the $12 million Frost Group line of credit and the $4 million Horizon term loan, specifically regarding interest rates (10% and 12.23% respectively) and repayment schedules.
- Dilution: Assess the impact of outstanding options (16 million), warrants (28 million), and convertible preferred stock (Series C) on future share count and earnings per share.
- Subsequent Events: Note the $5.0 million investment in Ophthalmic Technologies, Inc. (OTI) announced in April 2007 and the settlement agreement with the former President.